PARP Inhibitors Market Size by Drug-type, Indication, Distribution Channels, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2032
11.1%
CAGR (2025-2032)
6.82 USD Bn.
Market Size
319
Report Pages
145
Market Tables
Overview
The PARP Inhibitors Market size was valued at USD 6.82 Billion in 2024 and the total PARP Inhibitors revenue is expected to grow at a CAGR of 11.1% from 2025 to 2032, reaching nearly USD 15.84 Billion.
PARP Inhibitors Market Introduction and Overview
Cancer is the most devastating disease of our time. According to the World Health Organisation, it is the second most cause of death globally. The globally increasing prevalence of cancer has increased the demand for efficient drugs, targeted therapies, and precision medicines. Precision medicines have revolutionized cancer therapies by the concept of targeting selective cancer cells. Over the past decade Poly ADP-ribose Polymerases (PARP) have emerged as a new target in cancer therapy.
To know about the Research Methodology :- Request Free Sample Report
PARP inhibitors are a successful example of precision medicine, as the first drugs targeting specific cancer cells. They work by preventing cells from repairing their DNA which is damaged by the chemotherapy agents. Moreover, a combination of chemotherapy and PARP inhibitors can help in reducing the proliferation of cancer cells.
Rising cancer cases, funding initiatives by governments, and advanced treatment techniques are elevating the PARP inhibitors market. Cancer Australia’s “Supporting people with Cancer” grant initiative provides organisation with grants up to $120,000 to support projects aimed at reducing the cancer burden. Effective partnerships between organisations to improve coordination, accessibility, and development of quality cancer support networks are also responsible for the market growth.
Strict government regulations may restrain the market from growing.
PARP Inhibitors Market Segment Analysis
The drug type segment has dominated the Global PARP Inhibitors market. The increasing demand for drugs is boosting the market growth. Increased number of product approvals such as Lynparza (Olaprib), Niraparib, and Rucaparib by the FDA for ovarian cancer have elevated the market. Moreover, several other PARP Inhibitors that exhibit promising results are in the last stages of clinical trials. In the Indication segment, Ovarian cancer held a dominant position in 2024. PARP Inhibitors are extensively used in ovarian cancer treatments as they help repair damaged DNA.
PARP Inhibitors Market Regional Insights
North America holds a dominant position in the global PARP inhibitors market. Owing to the rising prevalence of the geriatric population and the large number of diseases and disorders, the region’s dominance is high. The rising elderly population is likely to drive the global PARP Inhibitors Market during the forecast period. Increasing research on BRCA-mutation tumours, ovarian cancer, and awareness about the disease is generating a revenue potential for the market in the APAC region.
The objective of the report is to present a comprehensive analysis of the Global PARP Inhibitors Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global PARP Inhibitors Marketdynamics, structure by analyzing the market segments and project the Global PARP Inhibitors Marketsize. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in Global Market make the report investor’s guide.
PARP Inhibitors Market Scope: Inquire before buying
| Global PARP Inhibitors Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 6.82 Bn. |
| Forecast Period 2025 to 2032 CAGR: | 11.1% | Market Size in 2032: | USD 15.84 Bn. |
| Segments Covered: | by Drug-type | Lynparza Niraparib Rucaparib Talazoparib Veliparib |
|
| by Indication | Ovarian Cancer Breast Cancer Prostate Cancer Pancreatic Cancer |
||
| by Distribution Channels | Hospital Pharmacies Retail Pharmacies Online Pharmacies |
||
PARP Inhibitors Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
PARP Inhibitors Market, Key Players
1. AstraZeneca
2. Tesaro
3. AbbVie Inc
4. Medivation
5. Clovis Oncology
6. Johnson & Johnson
7. GlaxoSmithKline plc
8. Pfizer Inc
9. Bristol-Myers Squibb
10.Merck KGaA
11.Genentech Inc
12.Repare Therapeutics
13.Sierra Oncology
14.Karyopharm Therapeutics Inc
15.Ono Pharmaceutical Co. Ltd
Frequently Asked Questions:
1. Which region has the largest share in Global Parp Inhibitors Market?
Ans: North America region held the highest share in 2024.
2. What was the Global PARP Inhibitors Market size in 2024?
Ans: The Global PARP Inhibitors Market size was USD 6.82 Billion in 2024.
3. What is scope of the Global Parp Inhibitors market report?
Ans: Global Parp Inhibitors Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Parp Inhibitors market?
Ans: The important key players in the Global Market are AstraZeneca, Tesaro, AbbVie Inc, Medivation, Clovis Oncology, Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc, Bristol-Myers Squibb, Merck KGaA, Genentech Inc, Repare Therapeutics, Sierra Oncology, Karyopharm Therapeutics Inc, and Ono Pharmaceutical Co. Ltd.
5. What is the study period of this market?
Ans: The Global Parp Inhibitors Market is studied from 2024 to 2032.
Table of Contents
Global PARP Inhibitors Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: PARP Inhibitors MarketSize, By Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global PARP Inhibitors MarketAnalysis and Forecast
6.1. PARP Inhibitors MarketSize & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global PARP Inhibitors MarketAnalysis and Forecast, By Drug-type
7.1. Introduction and Definition
7.2. Key Findings
7.3. PARP Inhibitors MarketValue Share Analysis, By Drug-type
7.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Drug-type
7.5. PARP Inhibitors MarketAnalysis, By Drug-type
7.6. PARP Inhibitors MarketAttractiveness Analysis, By Drug-type
8. Global PARP Inhibitors MarketAnalysis and Forecast, By Indication
8.1. Introduction and Definition
8.2. Key Findings
8.3. PARP Inhibitors MarketValue Share Analysis, By Indication
8.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Indication
8.5. PARP Inhibitors MarketAnalysis, By Indication
8.6. PARP Inhibitors MarketAttractiveness Analysis, By Indication
9. Global PARP Inhibitors MarketAnalysis and Forecast By Distribution Channels
9.1. Introduction and Definition
9.2. Key Findings
9.3. PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
9.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Distribution Channels
9.5. PARP Inhibitors MarketAnalysis, By Distribution Channels
9.6. PARP Inhibitors MarketAttractiveness Analysis, By Distribution Channels
10. Global PARP Inhibitors MarketAnalysis, By Region
10.1. PARP Inhibitors MarketValue Share Analysis, By Region
10.2. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Region
10.3. PARP Inhibitors MarketAttractiveness Analysis, By Region
11. North America PARP Inhibitors MarketAnalysis
11.1. Key Findings
11.2. North America PARP Inhibitors MarketOverview
11.3. North America PARP Inhibitors MarketValue Share Analysis, By Drug-type
11.4. North America PARP Inhibitors MarketForecast, By Drug-type
11.4.1. Lynparza
11.4.2. Niraparib
11.4.3. Rucaparib
11.4.4. Talazoparib
11.4.5. Veliparib
11.5. North America PARP Inhibitors MarketValue Share Analysis, By Indication
11.6. North America PARP Inhibitors MarketForecast, By Indication
11.6.1. Ovarian Cancer
11.6.2. Breast Cancer
11.6.3. Prostate Cancer
11.6.4. Pancreatic Cancer
11.7. North America PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
11.8. North America PARP Inhibitors MarketForecast, By Distribution Channels
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. North America PARP Inhibitors MarketValue Share Analysis, By Country
11.10. North America PARP Inhibitors MarketForecast, By Country
11.10.1. U.S.
11.10.2. Canada
11.10.3. Mexico
11.11. North America PARP Inhibitors MarketAnalysis, By Country
11.12. U.S. PARP Inhibitors MarketForecast, By Drug-type
11.12.1. Lynparza
11.12.2. Niraparib
11.12.3. Rucaparib
11.12.4. Talazoparib
11.12.5. Veliparib
11.13. U.S. PARP Inhibitors MarketForecast, By Indication
11.13.1. Ovarian Cancer
11.13.2. Breast Cancer
11.13.3. Prostate Cancer
11.13.4. Pancreatic Cancer
11.14. U.S. PARP Inhibitors MarketForecast, By Distribution Channels
11.14.1. Hospital Pharmacies
11.14.2. Retail Pharmacies
11.14.3. Online Pharmacies
11.15. Canada PARP Inhibitors MarketForecast, By Drug-type
11.15.1. Lynparza
11.15.2. Niraparib
11.15.3. Rucaparib
11.15.4. Talazoparib
11.15.5. Veliparib
11.16. Canada PARP Inhibitors MarketForecast, By Indication
11.16.1. Ovarian Cancer
11.16.2. Breast Cancer
11.16.3. Prostate Cancer
11.16.4. Pancreatic Cancer
11.17. Canada PARP Inhibitors MarketForecast, By Distribution Channels
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Online Pharmacies
11.18. Mexico PARP Inhibitors MarketForecast, By Drug-type
11.18.1. Lynparza
11.18.2. Niraparib
11.18.3. Rucaparib
11.18.4. Talazoparib
11.18.5. Veliparib
11.19. Mexico PARP Inhibitors MarketForecast, By Indication
11.19.1. Ovarian Cancer
11.19.2. Breast Cancer
11.19.3. Prostate Cancer
11.19.4. Pancreatic Cancer
11.20. Mexico PARP Inhibitors MarketForecast, By Distribution Channels
11.20.1. Hospital Pharmacies
11.20.2. Retail Pharmacies
11.20.3. Online Pharmacies
11.21. North America PARP Inhibitors MarketAttractiveness Analysis
11.21.1. By Drug-type
11.21.2. By Indication
11.21.3. By Distribution Channels
11.22. PEST Analysis
11.23. Key Trends
11.24. Key Developments
12. Europe PARP Inhibitors MarketAnalysis
12.1. Key Findings
12.2. Europe PARP Inhibitors MarketOverview
12.3. Europe PARP Inhibitors MarketValue Share Analysis, By Drug-type
12.4. Europe PARP Inhibitors MarketForecast, By Drug-type
12.4.1. Lynparza
12.4.2. Niraparib
12.4.3. Rucaparib
12.4.4. Talazoparib
12.4.5. Veliparib
12.5. Europe PARP Inhibitors MarketValue Share Analysis, By Indication
12.6. Europe PARP Inhibitors MarketForecast, By Indication
12.6.1. Ovarian Cancer
12.6.2. Breast Cancer
12.6.3. Prostate Cancer
12.6.4. Pancreatic Cancer
12.7. Europe PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
12.8. Europe PARP Inhibitors MarketForecast, By Distribution Channels
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Europe PARP Inhibitors MarketValue Share Analysis, By Country
12.10. Europe PARP Inhibitors MarketForecast, By Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Sweden
12.10.7. CIS countries
12.10.8. Rest of Europe
12.11. Germany PARP Inhibitors MarketForecast, By Drug-type
12.11.1. Lynparza
12.11.2. Niraparib
12.11.3. Rucaparib
12.11.4. Talazoparib
12.11.5. Veliparib
12.12. Germany PARP Inhibitors MarketForecast, By Indication
12.12.1. Ovarian Cancer
12.12.2. Breast Cancer
12.12.3. Prostate Cancer
12.12.4. Pancreatic Cancer
12.13. Germany PARP Inhibitors MarketForecast, By Distribution Channels
12.13.1. Hospital Pharmacies
12.13.2. Retail Pharmacies
12.13.3. Online Pharmacies
12.14. U.K. PARP Inhibitors MarketForecast, By Drug-type
12.14.1. Lynparza
12.14.2. Niraparib
12.14.3. Rucaparib
12.14.4. Talazoparib
12.14.5. Veliparib
12.15. U.K. PARP Inhibitors MarketForecast, By Indication
12.15.1. Ovarian Cancer
12.15.2. Breast Cancer
12.15.3. Prostate Cancer
12.15.4. Pancreatic Cancer
12.16. U.K. PARP Inhibitors MarketForecast, By Distribution Channels
12.16.1. Hospital Pharmacies
12.16.2. Retail Pharmacies
12.16.3. Online Pharmacies
12.17. France PARP Inhibitors MarketForecast, By Drug-type
12.17.1. Lynparza
12.17.2. Niraparib
12.17.3. Rucaparib
12.17.4. Talazoparib
12.17.5. Veliparib
12.18. France PARP Inhibitors MarketForecast, By Indication
12.18.1. Ovarian Cancer
12.18.2. Breast Cancer
12.18.3. Prostate Cancer
12.18.4. Pancreatic Cancer
12.19. France PARP Inhibitors MarketForecast, By Distribution Channels
12.19.1. Hospital Pharmacies
12.19.2. Retail Pharmacies
12.19.3. Online Pharmacies
12.20. Italy PARP Inhibitors MarketForecast, By Drug-type
12.20.1. Lynparza
12.20.2. Niraparib
12.20.3. Rucaparib
12.20.4. Talazoparib
12.20.5. Veliparib
12.21. Italy PARP Inhibitors MarketForecast, By Indication
12.21.1. Ovarian Cancer
12.21.2. Breast Cancer
12.21.3. Prostate Cancer
12.21.4. Pancreatic Cancer
12.22. Italy PARP Inhibitors MarketForecast, By Distribution Channels
12.22.1. Hospital Pharmacies
12.22.2. Retail Pharmacies
12.22.3. Online Pharmacies
12.23. Spain PARP Inhibitors MarketForecast, By Drug-type
12.23.1. Lynparza
12.23.2. Niraparib
12.23.3. Rucaparib
12.23.4. Talazoparib
12.23.5. Veliparib
12.24. Spain PARP Inhibitors MarketForecast, By Indication
12.24.1. Ovarian Cancer
12.24.2. Breast Cancer
12.24.3. Prostate Cancer
12.24.4. Pancreatic Cancer
12.25. Spain PARP Inhibitors MarketForecast, By Distribution Channels
12.25.1. Hospital Pharmacies
12.25.2. Retail Pharmacies
12.25.3. Online Pharmacies
12.26. Sweden PARP Inhibitors MarketForecast, By Drug-type
12.26.1. Lynparza
12.26.2. Niraparib
12.26.3. Rucaparib
12.26.4. Talazoparib
12.26.5. Veliparib
12.27. Sweden PARP Inhibitors MarketForecast, By Indication
12.27.1. Ovarian Cancer
12.27.2. Breast Cancer
12.27.3. Prostate Cancer
12.27.4. Pancreatic Cancer
12.28. Sweden PARP Inhibitors MarketForecast, By Distribution Channels
12.28.1. Hospital Pharmacies
12.28.2. Retail Pharmacies
12.28.3. Online Pharmacies
12.29. CIS countries PARP Inhibitors MarketForecast, By Drug-type
12.29.1. Lynparza
12.29.2. Niraparib
12.29.3. Rucaparib
12.29.4. Talazoparib
12.29.5. Veliparib
12.30. CIS countries PARP Inhibitors MarketForecast, By Indication
12.30.1. Ovarian Cancer
12.30.2. Breast Cancer
12.30.3. Prostate Cancer
12.30.4. Pancreatic Cancer
12.31. CIS countries PARP Inhibitors MarketForecast, By Distribution Channels
12.31.1. Hospital Pharmacies
12.31.2. Retail Pharmacies
12.31.3. Online Pharmacies
12.32. Rest of Europe PARP Inhibitors MarketForecast, By Drug-type
12.32.1. Lynparza
12.32.2. Niraparib
12.32.3. Rucaparib
12.32.4. Talazoparib
12.32.5. Veliparib
12.33. Rest of Europe PARP Inhibitors MarketForecast, By Indication
12.33.1. Ovarian Cancer
12.33.2. Breast Cancer
12.33.3. Prostate Cancer
12.33.4. Pancreatic Cancer
12.34. Rest of Europe PARP Inhibitors MarketForecast, By Distribution Channels
12.34.1. Hospital Pharmacies
12.34.2. Retail Pharmacies
12.34.3. Online Pharmacies
12.35. Europe PARP Inhibitors MarketAttractiveness Analysis
12.35.1. By Indication
12.35.2. By Drug-type
12.35.3. By Distribution Channels
12.36. PEST Analysis
12.37. Key Trends
12.38. Key Developments
13. Asia Pacific PARP Inhibitors MarketAnalysis
13.1. Key Findings
13.2. Asia Pacific PARP Inhibitors MarketOverview
13.3. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Drug-type
13.4. Asia Pacific PARP Inhibitors MarketForecast, By Drug-type
13.4.1. Lynparza
13.4.2. Niraparib
13.4.3. Rucaparib
13.4.4. Talazoparib
13.4.5. Veliparib
13.5. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Indication
13.6. Asia Pacific PARP Inhibitors MarketForecast, By Indication
13.6.1. Ovarian Cancer
13.6.2. Breast Cancer
13.6.3. Prostate Cancer
13.6.4. Pancreatic Cancer
13.7. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
13.8. Asia Pacific PARP Inhibitors MarketForecast, By Distribution Channels
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Country
13.10. Asia Pacific PARP Inhibitors MarketForecast, By Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. South Korea
13.10.5. Australia
13.10.6. ASEAN
13.10.7. Rest of Asia Pacific
13.11. Asia Pacific PARP Inhibitors MarketAnalysis, By Country
13.12. China PARP Inhibitors MarketForecast, By Drug-type
13.12.1. Lynparza
13.12.2. Niraparib
13.12.3. Rucaparib
13.12.4. Talazoparib
13.12.5. Veliparib
13.13. China PARP Inhibitors MarketForecast, By Indication
13.13.1. Ovarian Cancer
13.13.2. Breast Cancer
13.13.3. Prostate Cancer
13.13.4. Pancreatic Cancer
13.14. China PARP Inhibitors MarketForecast, By Distribution Channels
13.14.1. Hospital Pharmacies
13.14.2. Retail Pharmacies
13.14.3. Online Pharmacies
13.15. India PARP Inhibitors MarketForecast, By Drug-type
13.15.1. Lynparza
13.15.2. Niraparib
13.15.3. Rucaparib
13.15.4. Talazoparib
13.15.5. Veliparib
13.16. India PARP Inhibitors MarketForecast, By Indication
13.16.1. Ovarian Cancer
13.16.2. Breast Cancer
13.16.3. Prostate Cancer
13.16.4. Pancreatic Cancer
13.17. India PARP Inhibitors MarketForecast, By Distribution Channels
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Online Pharmacies
13.18. Japan PARP Inhibitors MarketForecast, By Drug-type
13.18.1. Lynparza
13.18.2. Niraparib
13.18.3. Rucaparib
13.18.4. Talazoparib
13.18.5. Veliparib
13.19. Japan PARP Inhibitors MarketForecast, By Indication
13.19.1. Ovarian Cancer
13.19.2. Breast Cancer
13.19.3. Prostate Cancer
13.19.4. Pancreatic Cancer
13.20. Japan PARP Inhibitors MarketForecast, By Distribution Channels
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Online Pharmacies
13.21. South Korea PARP Inhibitors MarketForecast, By Drug-type
13.21.1. Lynparza
13.21.2. Niraparib
13.21.3. Rucaparib
13.21.4. Talazoparib
13.21.5. Veliparib
13.22. South Korea PARP Inhibitors MarketForecast, By Indication
13.22.1. Ovarian Cancer
13.22.2. Breast Cancer
13.22.3. Prostate Cancer
13.22.4. Pancreatic Cancer
13.23. South Korea PARP Inhibitors MarketForecast, By Distribution Channels
13.23.1. Hospital Pharmacies
13.23.2. Retail Pharmacies
13.23.3. Online Pharmacies
13.24. Australia PARP Inhibitors MarketForecast, By Drug-type
13.24.1. Lynparza
13.24.2. Niraparib
13.24.3. Rucaparib
13.24.4. Talazoparib
13.24.5. Veliparib
13.25. Australia PARP Inhibitors MarketForecast, By Indication
13.25.1. Ovarian Cancer
13.25.2. Breast Cancer
13.25.3. Prostate Cancer
13.25.4. Pancreatic Cancer
13.26. Australia PARP Inhibitors MarketForecast, By Distribution Channels
13.26.1. Hospital Pharmacies
13.26.2. Retail Pharmacies
13.26.3. Online Pharmacies
13.27. ASEAN PARP Inhibitors MarketForecast, By Drug-type
13.27.1. Lynparza
13.27.2. Niraparib
13.27.3. Rucaparib
13.27.4. Talazoparib
13.27.5. Veliparib
13.28. ASEAN PARP Inhibitors MarketForecast, By Indication
13.28.1. Ovarian Cancer
13.28.2. Breast Cancer
13.28.3. Prostate Cancer
13.28.4. Pancreatic Cancer
13.29. ASEAN PARP Inhibitors MarketForecast, By Distribution Channels
13.29.1. Hospital Pharmacies
13.29.2. Retail Pharmacies
13.29.3. Online Pharmacies
13.30. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Drug-type
13.30.1. Lynparza
13.30.2. Niraparib
13.30.3. Rucaparib
13.30.4. Talazoparib
13.30.5. Veliparib
13.31. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Indication
13.31.1. Ovarian Cancer
13.31.2. Breast Cancer
13.31.3. Prostate Cancer
13.31.4. Pancreatic Cancer
13.32. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Distribution Channels
13.32.1. Hospital Pharmacies
13.32.2. Retail Pharmacies
13.32.3. Online Pharmacies
13.33. Asia Pacific PARP Inhibitors MarketAttractiveness Analysis
13.33.1. By Drug-type
13.33.2. By Indication
13.33.3. By Distribution Channels
13.34. PEST Analysis
13.35. Key Trends
13.36. Key Developments
14. Middle East & Africa PARP Inhibitors MarketAnalysis
14.1. Key Findings
14.2. Middle East & Africa PARP Inhibitors MarketOverview
14.3. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Drug-type
14.4. Middle East & Africa PARP Inhibitors MarketForecast, By Drug-type
14.4.1. Lynparza
14.4.2. Niraparib
14.4.3. Rucaparib
14.4.4. Talazoparib
14.4.5. Veliparib
14.5. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Indication
14.6. Middle East & Africa PARP Inhibitors MarketForecast, By Indication
14.6.1. Ovarian Cancer
14.6.2. Breast Cancer
14.6.3. Prostate Cancer
14.6.4. Pancreatic Cancer
14.7. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
14.8. Middle East & Africa PARP Inhibitors MarketForecast, By Distribution Channels
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Country
14.10. Middle East & Africa PARP Inhibitors MarketForecast, By Country
14.10.1. GCC Countries
14.10.2. South Africa
14.10.3. Nigeria
14.10.4. Egypt
14.10.5. Rest of Middle East & Africa
14.11. Middle East & Africa PARP Inhibitors MarketAnalysis, By Country
14.12. GCC Countries PARP Inhibitors MarketForecast, By Drug-type
14.12.1. Lynparza
14.12.2. Niraparib
14.12.3. Rucaparib
14.12.4. Talazoparib
14.12.5. Veliparib
14.13. GCC Countries PARP Inhibitors MarketForecast, By Indication
14.13.1. Ovarian Cancer
14.13.2. Breast Cancer
14.13.3. Prostate Cancer
14.13.4. Pancreatic Cancer
14.14. GCC Countries PARP Inhibitors MarketForecast, By Distribution Channels
14.14.1. Hospital Pharmacies
14.14.2. Retail Pharmacies
14.14.3. Online Pharmacies
14.15. South Africa PARP Inhibitors MarketForecast, By Drug-type
14.15.1. Lynparza
14.15.2. Niraparib
14.15.3. Rucaparib
14.15.4. Talazoparib
14.15.5. Veliparib
14.16. South Africa PARP Inhibitors MarketForecast, By Indication
14.16.1. Ovarian Cancer
14.16.2. Breast Cancer
14.16.3. Prostate Cancer
14.16.4. Pancreatic Cancer
14.17. South Africa PARP Inhibitors MarketForecast, By Distribution Channels
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Online Pharmacies
14.18. Nigeria PARP Inhibitors MarketForecast, By Drug-type
14.18.1. Lynparza
14.18.2. Niraparib
14.18.3. Rucaparib
14.18.4. Talazoparib
14.18.5. Veliparib
14.19. Nigeria PARP Inhibitors MarketForecast, By Indication
14.19.1. Ovarian Cancer
14.19.2. Breast Cancer
14.19.3. Prostate Cancer
14.19.4. Pancreatic Cancer
14.20. Nigeria PARP Inhibitors MarketForecast, By Distribution Channels
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Online Pharmacies
14.21. Egypt PARP Inhibitors MarketForecast, By Drug-type
14.21.1. Lynparza
14.21.2. Niraparib
14.21.3. Rucaparib
14.21.4. Talazoparib
14.21.5. Veliparib
14.22. Egypt PARP Inhibitors MarketForecast, By Indication
14.22.1. Ovarian Cancer
14.22.2. Breast Cancer
14.22.3. Prostate Cancer
14.22.4. Pancreatic Cancer
14.23. Egypt PARP Inhibitors MarketForecast, By Distribution Channels
14.23.1. Hospital Pharmacies
14.23.2. Retail Pharmacies
14.23.3. Online Pharmacies
14.24. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Drug-type
14.24.1. Lynparza
14.24.2. Niraparib
14.24.3. Rucaparib
14.24.4. Talazoparib
14.24.5. Veliparib
14.25. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Indication
14.25.1. Ovarian Cancer
14.25.2. Breast Cancer
14.25.3. Prostate Cancer
14.25.4. Pancreatic Cancer
14.26. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Distribution Channels
14.26.1. Hospital Pharmacies
14.26.2. Retail Pharmacies
14.26.3. Online Pharmacies
14.27. Middle East & Africa PARP Inhibitors MarketAttractiveness Analysis
14.27.1. By Drug-type
14.27.2. By Indication
14.27.3. By Distribution Channels
14.28. PEST Analysis
14.29. Key Trends
14.30. Key Developments
15. South America PARP Inhibitors MarketAnalysis
15.1. Key Findings
15.2. South America PARP Inhibitors MarketOverview
15.3. South America PARP Inhibitors MarketValue Share Analysis, By Drug-type
15.4. South America PARP Inhibitors MarketForecast, By Drug-type
15.4.1. Lynparza
15.4.2. Niraparib
15.4.3. Rucaparib
15.4.4. Talazoparib
15.4.5. Veliparib
15.5. South America PARP Inhibitors MarketValue Share Analysis, By Indication
15.6. South America PARP Inhibitors MarketForecast, By Indication
15.6.1. Ovarian Cancer
15.6.2. Breast Cancer
15.6.3. Prostate Cancer
15.6.4. Pancreatic Cancer
15.7. South America PARP Inhibitors MarketValue Share Analysis, By Distribution Channels
15.8. South America PARP Inhibitors MarketForecast, By Distribution Channels
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. South America PARP Inhibitors MarketValue Share Analysis, By Country
15.10. South America PARP Inhibitors MarketForecast, By Country
15.10.1. Brazil
15.10.2. Colombia
15.10.3. Argentina
15.10.4. Rest of South America
15.11. South America PARP Inhibitors MarketAnalysis, By Country
15.12. Brazil PARP Inhibitors MarketForecast, By Drug-type
15.12.1. Lynparza
15.12.2. Niraparib
15.12.3. Rucaparib
15.12.4. Talazoparib
15.12.5. Veliparib
15.13. Brazil PARP Inhibitors MarketForecast, By Indication
15.13.1. Ovarian Cancer
15.13.2. Breast Cancer
15.13.3. Prostate Cancer
15.13.4. Pancreatic Cancer
15.14. Brazil PARP Inhibitors MarketForecast, By Distribution Channels
15.14.1. Hospital Pharmacies
15.14.2. Retail Pharmacies
15.14.3. Online Pharmacies
15.15. Colombia PARP Inhibitors MarketForecast, By Drug-type
15.15.1. Lynparza
15.15.2. Niraparib
15.15.3. Rucaparib
15.15.4. Talazoparib
15.15.5. Veliparib
15.16. Colombia PARP Inhibitors MarketForecast, By Indication
15.16.1. Ovarian Cancer
15.16.2. Breast Cancer
15.16.3. Prostate Cancer
15.16.4. Pancreatic Cancer
15.17. Colombia PARP Inhibitors MarketForecast, By Distribution Channels
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Online Pharmacies
15.18. Argentina PARP Inhibitors MarketForecast, By Drug-type
15.18.1. Lynparza
15.18.2. Niraparib
15.18.3. Rucaparib
15.18.4. Talazoparib
15.18.5. Veliparib
15.19. Argentina PARP Inhibitors MarketForecast, By Indication
15.19.1. Ovarian Cancer
15.19.2. Breast Cancer
15.19.3. Prostate Cancer
15.19.4. Pancreatic Cancer
15.20. Argentina PARP Inhibitors MarketForecast, By Distribution Channels
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Online Pharmacies
15.21. Rest of South America PARP Inhibitors MarketForecast, By Drug-type
15.21.1. Lynparza
15.21.2. Niraparib
15.21.3. Rucaparib
15.21.4. Talazoparib
15.21.5. Veliparib
15.22. Rest of South America PARP Inhibitors MarketForecast, By Indication
15.22.1. Ovarian Cancer
15.22.2. Breast Cancer
15.22.3. Prostate Cancer
15.22.4. Pancreatic Cancer
15.23. Rest of South America PARP Inhibitors MarketForecast, By Distribution Channels
15.23.1. Hospital Pharmacies
15.23.2. Retail Pharmacies
15.23.3. Online Pharmacies
15.24. South America PARP Inhibitors MarketAttractiveness Analysis
15.24.1. By Drug-type
15.24.2. By Indication
15.24.3. By Distribution Channels
15.25. PEST Analysis
15.26. Key Trends
15.27. Key Developments
16. Company Profiles
16.1. Market Share Analysis, By Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players By price, presence, market share, Indication, and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A By Regions, Investment and Indication
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. AstraZeneca
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Tesaro
16.3.3. AbbVie Inc
16.3.4. Medivation
16.3.5. Clovis Oncology
16.3.6. Johnson & Johnson
16.3.7. GlaxoSmithKline plc
16.3.8. Pfizer Inc
16.3.9. Bristol-Myers Squibb
16.3.10. Merck KGaA
16.3.11. Genentech Inc
16.3.12. Repare Therapeutics
16.3.13. Sierra Oncology
16.3.14. Karyopharm Therapeutics Inc
16.3.15. Ono Pharmaceutical Co. Ltd